FDA Biologics & Clinical Pipeline
Material regulatory developments from FDA CBER are tracked daily by Cresthaven Analytics. Over the last 90 days, 20 material briefs relevant to professionals operating in the healthcare & life sciences sector have been published below. Each brief is sourced directly from the primary regulatory feed, summarized for institutional readers, and scored for materiality.
Recent material activity
-
FDA maintains approved labeling page for Gammaplex 5% and 10% intravenous immunoglobulin products
On July 17, 2026, the FDA's Center for Biologics Evaluation and Research published or updated its approved blood products page for Gammaplex 5% and 10%. The page confirms approved indications for primary humoral immunode…
Read a full sample brief → -
FDA grants full approval to ALYGLO for primary humoral immunodeficiency in adults
The FDA approved ALYGLO, an intravenous immune globulin product, for the treatment of primary humoral immunodeficiency in adults, with the approval posted July 17, 2026. This action adds a new licensed biological product…
Read a full sample brief → -
FDA issues Ebola donor eligibility guidance for all HCT/P establishments nationwide
On July 16, 2026, the FDA issued a safety communication directing human cell, tissue, and cellular and tissue-based product (HCT/P) establishments on Ebola disease considerations for donor eligibility determinations. The…
Read a full sample brief → -
FDA grants first-ever approval for a chikungunya virus vaccine for adults 18 and older
The FDA has approved Ixchiq, a live attenuated chikungunya vaccine developed by Valneva — the first licensed vaccine for chikungunya virus disease in the United States. This approval creates a new licensed product catego…
Read a full sample brief → -
FDA Biologics & Clinical Pipeline release pending Cresthaven Analytics full analysis: Procleix Ultrio Assay
FDA Biologics & Clinical Pipeline published a regulatory release titled 'Procleix Ultrio Assay'. Cresthaven Analytics' full intelligence brief is pending re-analysis; see the source link below for the complete primary te…
Read a full sample brief → -
FDA licenses MD Anderson Cord Blood Bank HPC cord blood product for unrelated donor hematopoietic transplantation
The FDA has issued a biologics license to the MD Anderson Cord Blood Bank for a hematopoietic progenitor cell cord blood product indicated for unrelated donor transplantation with an appropriate preparative regimen. The …
Read a full sample brief → -
FDA updates product approval record for Procleix Ultrio Plus Assays covering donor screening indications
On July 8, 2026, the FDA posted updated approval information for the Procleix Ultrio Plus Assay. The record covers screening of organ donors using beating-heart specimens, cadaveric donor blood specimens, and individual …
Read a full sample brief → -
FDA approves Roche Elecsys Chagas immunoassay for blood donor screening
The FDA has approved Elecsys Chagas, a Roche in vitro immunoassay, for qualitative detection of Trypanosoma cruzi antibodies in human serum and plasma. The device is indicated for screening individual human donors, inclu…
Read a full sample brief → -
FDA confirms approved indication for FIBRYGA in congenital fibrinogen deficiency across adult and adolescent populations
FIBRYGA is approved by the FDA for acute bleeding episodes in adults and adolescents with congenital fibrinogen deficiency, covering both afibrinogenemia and hypofibrinogenemia. The blood products registry listing reflec…
Read a full sample brief → -
FDA maintains Quadracel approval for fifth-dose DTaP series use in children aged 4 through 6
Quadracel is FDA-approved for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis. A single dose is authorized for children 4 through 6 years of age as the fifth dose in the DTaP vaccination ser…
Read a full sample brief → -
FDA confirms NUWIQ approval for hemophilia A across on-demand, perioperative, and prophylactic indications
The FDA has approved NUWIQ (simoctocog alfa), a recombinant factor VIII product, for adults and children with Hemophilia A. The approval covers on-demand bleeding treatment, perioperative bleeding management, and routine…
Read a full sample brief → -
FDA Biologics & Clinical Pipeline release pending Cresthaven Analytics full analysis: GLASSIA
FDA Biologics & Clinical Pipeline published a regulatory release titled 'GLASSIA'. Cresthaven Analytics' full intelligence brief is pending re-analysis; see the source link below for the complete primary text.
Read a full sample brief → -
FDA expands Casgevy gene therapy approval to patients aged 2 and older for sickle cell disease and beta thalassemia
The FDA issued a supplemental approval on July 1, 2026 for Casgevy (exagamglogene autotemcel), extending its indicated population to patients aged 2 years and older with sickle cell disease with recurrent vaso-occlusive …
Read a full sample brief → -
FDA extends expiration of North American Coral Snake Antivenin Lot CL6814 through December 31, 2026
FDA extended the expiration date of North American Coral Snake Antivenin (Micrurus fulvius) (Equine Origin) Lot CL6814 to December 31, 2026, via a biologics safety communication issued July 1, 2026. This lot remains the …
Read a full sample brief → -
FDA issues guidance on next-generation sequencing data submission standards for antiviral drug applications
On July 1, 2026, the FDA's Division of Antiviral Products issued guidance establishing submission standards for next-generation sequencing data in antiviral drug applications. The guidance sets out electronic submission …
Read a full sample brief → -
FDA grants first-in-class approval for Treg cell immunotherapy TREGZI in allogeneic stem cell transplant patients
The FDA approved TREGZI on June 30, 2026 — the first regulatory T cell-based immunotherapy authorized in the United States. The approval covers improving chronic graft-versus-host disease-free survival in adults with blo…
Read a full sample brief → -
FDA issues CGMP warning letter to Genzyme Ireland Limited citing biologics manufacturing deviations
The FDA issued a warning letter dated June 22, 2026 to Genzyme Ireland Limited citing current good manufacturing practice violations and deviations under the firm's Biologics License Application. This action reflects act…
Read a full sample brief → -
FDA formally designates Ebola disease a transfusion-transmitted infection, triggering binding donor screening obligations for all blood establishments
On June 29, 2026, FDA issued final guidance formally classifying Ebola disease as a transfusion-transmitted infection under federal blood safety regulations. The designation activates mandatory requirements for donor eli…
Read a full sample brief → -
FDA accepts rolling BLA Part 1 of 2 for mRESVIA RSV vaccine indication in adults 60 and older
The FDA posted a rolling Biologics License Application filing update for mRESVIA on June 29, 2026, covering active immunization against lower respiratory tract disease and acute respiratory disease caused by RSV in adult…
Read a full sample brief → -
FDA approves COBAS TaqScreen West Nile Virus Test for donor screening across blood, plasma, and organ donation
The FDA approved the COBAS TaqScreen West Nile Virus Test for qualitative detection of West Nile Virus RNA in plasma specimens from individual human donors, whole blood and blood component donors, and living organ donors…
Read a full sample brief →
Get every FDA Biologics & Clinical Pipeline brief delivered the day it lands
From $149/month
Cresthaven Analytics monitors FDA CBER continuously, applying institutional materiality scoring to every release. Subscribers receive structured briefs via email, portal, and (Executive tier and above) real-time alerts.
View all tiers →